Capital International Investors Purchases 778,467 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Capital International Investors increased its stake in Zimmer Biomet by 11.5%, acquiring 778,467 shares to hold 7,550,754 shares (about 3.81% of the company) valued at roughly $743.75 million.
• Zimmer Biomet beat quarterly estimates with $2.42 EPS (vs. $2.38 expected) and $2.24 billion in revenue (vs. $2.22 billion), reported revenue growth of 10.9% year-over-year, and set FY2026 guidance of 8.300–8.450 EPS.
• Analyst coverage is mixed and the consensus rating is Hold with a consensus target price of $106.20 (coverage breakdown: 1 Strong Buy, 8 Buy, 10 Hold, 3 Sell).

Capital International Investors raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11.5% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 7,550,754 shares of the medical equipment provider's stock after acquiring an additional 778,467 shares during the period. Capital International Investors owned about 3.81% of Zimmer Biomet worth $743,749,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZBH. Key Financial Inc lifted its position in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. lifted its position in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock worth $29,000 after buying an additional 116 shares in the last quarter. Root Financial Partners LLC acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth about $31,000. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 149 shares in the last quarter. Finally, Mather Group LLC. acquired a new stake in shares of Zimmer Biomet in the third quarter valued at about $36,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. UBS Group restated a "sell" rating and issued a $89.00 price target on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Weiss Ratings reissued a "hold (c-)" rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. BTIG Research restated a "buy" rating and set a $112.00 target price on shares of Zimmer Biomet in a report on Tuesday, February 10th. Wall Street Zen lowered shares of Zimmer Biomet from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. Finally, Robert W. Baird reiterated a "neutral" rating and issued a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and a consensus target price of $106.20.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $91.78 on Wednesday. Zimmer Biomet Holdings, Inc. has a 12-month low of $84.59 and a 12-month high of $114.44. The firm has a market capitalization of $17.96 billion, a price-to-earnings ratio of 25.93, a P/E/G ratio of 1.91 and a beta of 0.58. The stock's 50 day moving average price is $92.21 and its two-hundred day moving average price is $95.41. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet's payout ratio is 27.12%.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.